Editas Medicine, Inc. — Q1 2024 Form 10-Q
Business context and period. Clinical-stage gene-editing company; this unaudited report covers the three months ended March 31, 2024, compared with Q1 2023. Editas has no product sales and remains dependent on financing and collaboration and license payments.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Collaboration and other R&D revenue | $1.1 million | $9.9 million |
| Research and development expense | $48.8 million | $37.8 million |
| General and administrative expense | $19.3 million | $23.0 million |
| Operating loss | $67.0 million | $51.0 million |
| Net loss | $62.0 million | $49.0 million |
| Net loss per share, basic and diluted | $0.76 | $0.71 |
| Net cash used in operating activities | $49.9 million | $35.8 million |
At March 31, 2024, cash and cash equivalents were $69.2 million and marketable securities totaled $307.5 million, or $376.8 million combined. Total assets were $440.3 million; total liabilities were $145.9 million; stockholders’ equity was $294.4 million. The balance sheet reports lease liabilities and deferred revenue, but no borrowings are identified in the provided filing text. No gross margin is presented.
Material changes and drivers
- Revenue fell 88%, primarily because Q1 2023 included revenue following the January 2023 sale of wholly owned oncology assets and related licenses.
- R&D expense increased 29%, mainly from higher external clinical and manufacturing costs supporting reni-cel, increased sublicense and license fees, and higher stock-based compensation.
- G&A expense decreased 16%, largely due to lower one-time professional-service expenses and reduced patent-related legal activity, partly offset by increased stock-based compensation and employee costs.
- Net loss widened by $12.9 million. Higher R&D expenses and lower revenue more than offset increased interest income.
- Cash, cash equivalents, and restricted cash declined $54.4 million during the quarter. Investing cash flow reflected purchases and maturities of marketable securities; these portfolio transactions are not equivalent to operating cash burn.
Outlook, risks, and unusual items
- Management expects existing cash, cash equivalents, and marketable securities to fund operations and capital expenditures for at least 12 months from the May 8, 2024 financial-statement issuance date. Separately, it forecasts funding into 2026 based on existing resources plus near-term Vertex license fees and a contingent Vertex payment; the contingent payment is not assured. The filing warns actual runway may be shorter and substantial additional capital will be required.
- Editas received the $10 million 2024 annual license fee from Vertex in Q1 and may receive a further $50 million contingent upfront payment and additional annual fees through 2034, subject to agreement terms. It must pay Broad and Harvard a mid-double-digit percentage of amounts received under the Vertex license related to their licensed Cas9 technology.
- Management expects additional clinical data from the RUBY sickle cell disease and EdiTHAL beta-thalassemia trials in mid-2024 and further data by year-end 2024. The adult RUBY cohort is enrolled; dosing continues, and multiple adolescents are enrolled. The company also said it remained on track for in vivo preclinical proof-of-concept for an undisclosed indication by year-end 2024. These are forward-looking expectations, not assured outcomes.
- In March 2024, Editas amended its BMS/Juno collaboration, extending it to November 2026 with options for up to two additional years and allowing BMS to select up to three new research targets. The amendment carries $56.7 million of transaction price as deferred revenue; none was recognized in Q1 under the amendment.
- A manufacturing-space agreement is expected to commence in Q2 2024 and provides for up to $85.4 million of remaining payments over 10 years, with a termination right on 12 months’ notice. Existing non-cancelable operating lease payments totaled $40.3 million at quarter-end.
- Patent interference and opposition proceedings create an unquantifiable commitment to reimburse Broad and Harvard for related expenses; Q1 expense for these reimbursements was $2.0 million. Clinical, regulatory, manufacturing, intellectual-property, financing, and commercialization risks remain significant.
- The company reported an accumulated deficit of $1.3 billion and does not expect profitability in 2024 or the foreseeable future. Disclosure controls were assessed as effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Progress, safety, efficacy, enrollment, and timing of the next RUBY and EdiTHAL data updates.
- Whether and when the contingent $50 million Vertex payment is earned, and the timing and terms of future annual license fees.
- Cash burn and actual runway relative to management’s into-2026 estimate, including the assumptions behind that forecast.
- Future R&D spending, manufacturing-space commitments, and the scale and duration of Broad and Harvard patent-related reimbursements.
- Potential dilution or other financing terms if additional capital is required; the $300 million ATM facility had not been used as of March 31, 2024.
- Any material developments in intellectual-property disputes, collaboration milestones, or regulatory and clinical risks.